|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
69,020,000 |
Market
Cap: |
106.29(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.6003 - $4.53 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile NGM Biopharmaceuticals is a biopharmaceutical company. Co. has five product candidates in the clinic, three wholly-owned by Co. (NGM707, NGM120 and aldafermin), one being progressed by its collaborator, Merck Sharp & Dohme Corp., or Merck (MK-3655) and one optionable by Merck (NGM621). Co.'s oncology product candidates include NGM707, NGM831, NGM438 and NGM120 and their related compounds. NGM621 was engineered to bind to, and be a long-acting inhibitor of, complement C3 with the treatment goal of reducing disease progression in patients with geographic atrophy, secondary to age-related macular degeneration. MK-3655 isin Phase 2b development for the treatment of nonalcoholic steatohepatitis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
94,704 |
94,704 |
9,606,382 |
Total Buy Value |
$0 |
$64,854 |
$64,854 |
$87,820,003 |
Total People Bought |
0 |
4 |
4 |
5 |
Total Buy Transactions |
0 |
10 |
10 |
130 |
Total Shares Sold |
0 |
0 |
0 |
85,082 |
Total Sell Value |
$0 |
$0 |
$0 |
$438,308 |
Total People Sold |
0 |
0 |
0 |
1 |
Total Sell Transactions |
0 |
0 |
0 |
1 |
End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Tcg Iv Gp, Llc |
10% Owner |
|
2022-06-09 |
4 |
B |
$13.50 |
$13,286,174 |
I/I |
984,161 |
90,442 |
1.5 |
-71% |
|
Column Group Ii Gp, Lp |
General Partner |
|
2022-06-09 |
4 |
B |
$13.50 |
$13,286,174 |
I/I |
984,161 |
90,442 |
1.5 |
-71% |
|
Goeddel David V |
Director |
|
2022-06-09 |
4 |
B |
$13.50 |
$13,286,174 |
I/I |
984,161 |
90,442 |
2.25 |
-71% |
|
Column Group Ii Gp, Lp |
10% Owner |
|
2022-06-02 |
4 |
B |
$13.03 |
$445,739 |
I/I |
34,200 |
57,965 |
1.5 |
-13% |
|
Goeddel David V |
Director |
|
2022-06-02 |
4 |
B |
$13.03 |
$445,739 |
I/I |
34,200 |
57,965 |
2.25 |
-13% |
|
Tcg Iv Gp, Llc |
10% Owner |
|
2022-06-02 |
4 |
B |
$13.03 |
$445,739 |
I/I |
34,200 |
57,965 |
1.5 |
-13% |
|
Goeddel David V |
Director |
|
2022-06-01 |
4 |
B |
$13.45 |
$1,237,400 |
I/I |
92,000 |
56,836 |
2.25 |
-6% |
|
Column Group Ii Gp, Lp |
General Partner |
|
2022-06-01 |
4 |
B |
$13.45 |
$1,237,400 |
I/I |
92,000 |
56,836 |
1.5 |
-6% |
|
Tcg Iv Gp, Llc |
10% Owner |
|
2022-06-01 |
4 |
B |
$13.45 |
$1,237,400 |
I/I |
92,000 |
56,836 |
1.5 |
-6% |
|
Goeddel David V |
Director |
|
2022-05-31 |
4 |
B |
$13.47 |
$832,267 |
I/I |
61,806 |
53,800 |
2.25 |
-14% |
|
Column Group Ii Gp, Lp |
General Partner |
|
2022-05-31 |
4 |
B |
$13.47 |
$832,267 |
I/I |
61,806 |
53,800 |
1.5 |
-14% |
|
Tcg Iv Gp, Llc |
10% Owner |
|
2022-05-31 |
4 |
B |
$13.47 |
$832,267 |
I/I |
61,806 |
53,800 |
1.5 |
-14% |
|
Column Group Ii Gp, Lp |
General Partner |
|
2022-05-27 |
4 |
B |
$13.45 |
$36,453 |
I/I |
2,710 |
51,760 |
1.5 |
-12% |
|
Goeddel David V |
Director |
|
2022-05-27 |
4 |
B |
$13.45 |
$36,453 |
I/I |
2,710 |
51,760 |
2.25 |
-12% |
|
Tcg Iv Gp, Llc |
10% Owner |
|
2022-05-27 |
4 |
B |
$13.45 |
$36,453 |
I/I |
2,710 |
51,760 |
1.5 |
-12% |
|
Column Group Ii Gp, Lp |
General Partner |
|
2022-05-26 |
4 |
B |
$13.49 |
$272,582 |
I/I |
20,201 |
51,671 |
1.5 |
-8% |
|
Goeddel David V |
Director |
|
2022-05-26 |
4 |
B |
$13.49 |
$272,582 |
I/I |
20,201 |
51,671 |
2.25 |
-8% |
|
Tcg Iv Gp, Llc |
10% Owner |
|
2022-05-26 |
4 |
B |
$13.49 |
$272,582 |
I/I |
20,201 |
51,671 |
1.5 |
-8% |
|
Tcg Iv Gp, Llc |
10% Owner |
|
2022-05-25 |
4 |
B |
$13.43 |
$581,624 |
I/I |
43,292 |
51,004 |
1.5 |
-7% |
|
Goeddel David V |
Director |
|
2022-05-25 |
4 |
B |
$13.43 |
$581,624 |
I/I |
43,292 |
51,004 |
2.25 |
-7% |
|
Column Group Ii Gp, Lp |
General Partner |
|
2022-05-25 |
4 |
B |
$13.43 |
$581,624 |
I/I |
43,292 |
51,004 |
1.5 |
-7% |
|
Tcg Iv Gp, Llc |
10% Owner |
|
2022-05-24 |
4 |
B |
$13.37 |
$238,325 |
I/I |
17,828 |
49,575 |
1.5 |
-6% |
|
Goeddel David V |
Director |
|
2022-05-24 |
4 |
B |
$13.37 |
$238,325 |
I/I |
17,828 |
49,575 |
2.25 |
-6% |
|
Column Group Ii Gp, Lp |
General Partner |
|
2022-05-24 |
4 |
B |
$13.37 |
$238,325 |
I/I |
17,828 |
49,575 |
1.5 |
-6% |
|
Goeddel David V |
Director |
|
2022-05-20 |
4 |
B |
$13.48 |
$256,533 |
I/I |
19,034 |
48,987 |
2.25 |
-6% |
|
89 Records found
|
|
Page 1 of 4 |
|
|